Abstract
Mantle cell lymphoma (MCL) represents a distinct lymphoma subtype. The prognosis of patients with MCL is the poorest among lymphoma patients and the response to conventional treatments is inadequate. New approaches targeted to the biology of MCL and the genetics underlying the disease are being studied. Monoclonal antibodies directed at molecules expressed on MCL cells are already used in the clinical setting. This article reviews the literature on these and other new possible treatment modalities.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / biosynthesis
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Apoptosis
-
Clinical Trials as Topic
-
Cysteine Endopeptidases
-
Humans
-
Lymphoma, Mantle-Cell / pathology*
-
Lymphoma, Mantle-Cell / therapy*
-
Middle Aged
-
Multienzyme Complexes / antagonists & inhibitors
-
Proteasome Endopeptidase Complex
-
Rituximab
-
Treatment Outcome
-
Vaccines, DNA
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Multienzyme Complexes
-
Vaccines, DNA
-
Rituximab
-
ibritumomab tiuxetan
-
Cysteine Endopeptidases
-
Proteasome Endopeptidase Complex
-
tositumomab I-131